{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:05:54Z","timestamp":1791479154695,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["#24590495"],"award-info":[{"award-number":["#24590495"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Center for Advanced Molecular Medicine, Fukuoka University"},{"DOI":"10.13039\/501100005738","name":"Central Research Institute of Fukuoka University","doi-asserted-by":"crossref","award":["#171032"],"award-info":[{"award-number":["#171032"]}],"id":[{"id":"10.13039\/501100005738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.lungcan.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T12:06:32Z","timestamp":1551269192000},"page":"187-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia"],"prefix":"10.1016","volume":"130","author":[{"given":"Masayo","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-9869","authenticated-orcid":false,"given":"Tomoyuki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2019.02.004_bib0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.004_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2015.05.014","article-title":"Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England","volume":"89","author":"Damhuis","year":"2015","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.004_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"35","key":"10.1016\/j.lungcan.2019.02.004_bib0025","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000377697","volume":"59","author":"Hjerpe","year":"2015","journal-title":"Acta Cytol."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.004_bib0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2019.02.004_bib0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cncy.21269","article-title":"Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology","volume":"121","author":"Matsumoto","year":"2013","journal-title":"Cancer Cytopathol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.004_bib0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2559.2003.01686.x","article-title":"The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2","volume":"43","author":"Attanoos","year":"2003","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.lungcan.2019.02.004_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2559.2006.02442.x","article-title":"Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports","volume":"49","author":"King","year":"2006","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.004_bib0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0b013e31826ab1c0","article-title":"IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations","volume":"37","author":"Lee","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1309\/AJCP5KNL7QTELLYI","article-title":"Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells","volume":"141","author":"Minato","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.004_bib0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.lungcan.2013.12.009","article-title":"How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study","volume":"83","author":"Husain","year":"2014","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.004_bib0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/modpathol.3800732","article-title":"Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma","volume":"20","author":"Kato","year":"2007","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.004_bib0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","article-title":"The diagnostic utility of pre FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.004_bib0080","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-08-1363","article-title":"Identification of MCAM\/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma","volume":"69","author":"Bidlingmaier","year":"2009","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2019.02.004_bib0085","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/modpathol.2010.134","article-title":"Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium","volume":"23","author":"Sato","year":"2010","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.004_bib0095","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2019.02.004_bib0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol. Int."},{"key":"10.1016\/j.lungcan.2019.02.004_bib0105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.lungcan.2019.02.004_bib0110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.004_bib0115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of Somatic BAP1 alterations is sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2019.02.004_bib0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.lungcan.2019.02.004_bib0125","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.lungcan.2019.02.004_bib0130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"40","key":"10.1016\/j.lungcan.2019.02.004_bib0135","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2019.02.004_bib0140","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the bap1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.004_bib0145","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding og the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.004_bib0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.molcel.2014.03.002","article-title":"Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O","volume":"54","author":"Mashtalir","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lungcan.2019.02.004_bib0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol."},{"issue":"October","key":"10.1016\/j.lungcan.2019.02.004_bib0165","article-title":"A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritic","author":"Kinoshita","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb repressor complex-2 is a novel target for mesothelioma therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.004_bib0175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2019.02.004_bib0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","article-title":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","volume":"60","author":"McGregor","year":"2017","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.004_bib0185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jb\/mvu054","article-title":"Targeting histone methyltransferase EZH2 as cancer treatment","volume":"156","author":"Kondo","year":"2014","journal-title":"J. Biochem."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.004_bib0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1242\/dev.074450","article-title":"The role of the histone H2A ubiquitinase Sce in Polycomb repression","volume":"139","author":"Gutierrez","year":"2012","journal-title":"Development"},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.004_bib0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2019.02.004_bib0200","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.004_bib0205","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T04:06:13Z","timestamp":1555041973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219303095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":41,"alternative-id":["S0169500219303095"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}